ArticleFrontiers in drug safety and regulation2026
Evaluating the implementation of intermittent versus continuous fetal heart rate monitoring on intrapartum care and early neonatal outcomes using causal mediational modeling.
Article in Frontiers in drug safety and regulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intrapartum fetal heart rate (FHR) monitoring can detect fetal compromise and provide indications for early action. However, the effect of implementing intermittent vs. continuous FHR monitoring with Moyo remains unclear. In this study, we compare the effect of implementing intermittent vs. continuous FHR monitoring using Moyo on intrapartum care and neonatal outcomes. Methods: A prospective observational design was used to evaluate two different FHR monitoring methods in seven hospitals in Nepal, with intermittent monitoring as the control group and continuous monitoring as the intervention group. The durations from 1) first Moyo placement to abnormal FHR detection and 2) first abnormal FHR detection to childbirth were compared using generalized linear regression. The causal mediational method assessed the risk of non-crying neonates after birth and intrapartum stillbirth between the groups using the Mantel-Haenszel (M-H) homogeneity method, standardizing the risk for mediators and confounders. Results: A total of 1,091 participants were enrolled during the control period and 8,687 during the intervention period. Compared to the control group, the intervention group was associated with a non-significant reduction in time from first Moyo placement to abnormal FHR monitoring [adj.β = -35·5 min; 95% confidence interval (CI) = -73·2 to 2·22] and a significant reduction in time from first abnormal FHR to delivery (adj.β = -66·5 min; 95% CI = -106·2 to -26·8). The incidence of non-crying neonates was higher in the control group (11·5% vs. 10·0%), with an adjusted risk reduction of 31% (M-H RR = 0·69; 95% CI = 0·55-0·87) in the intervention group. The incidence of intrapartum stillbirth was non-significantly higher in the control group (4.5 vs. 3.0/1,000 births), with an adjusted risk reduced by 35% (M-H RR = 0·65; 95% CI = 0·25-1·70) in the intervention group. Conclusion: Compared with intermittent Moyo, the duration to detect abnormal FHR and the time from abnormal FHR to delivery were significantly reduced, with a 31% reduction in the risk of neonatal resuscitation with continuous Moyo. The implementation of continuous FHR monitoring with portal devices such as Moyo can reduce the time to action following the detection of abnormal fetal heart rates and decrease the burden of infants requiring neonatal resuscitation. Clinical Trial Registration: clinicaltrials.gov, identifier ISRCTN16741720.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.